Avacta Group PLC Issue of Equity (3083K)
09 April 2018 - 11:58PM
UK Regulatory
TIDMAVCT
RNS Number : 3083K
Avacta Group PLC
09 April 2018
9 April 2018
Avacta Group plc
("Avacta", "the Group" or "the Company")
Issue of Equity
Avacta Group plc (AIM: AVCT), the developer of Affimer(R)
biotherapeutics and research reagents, announces that application
has been made for 10,345 new ordinary shares of 10p each (the "New
Ordinary Shares") to be admitted to trading on AIM on 16 April 2018
("Admission").
The New Ordinary Shares have been allotted pursuant to the
purchase by Michael Albin, a Non-Executive Director of the Company
up to his resignation on 30 March 2018, of New Ordinary Shares in
accordance with the terms set out in the Company's announcement of
23 February 2016.
Following Admission, the total number of ordinary shares with
voting rights in issue will be 68,989,487. Shareholders may use
this figure as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the Financial
Conduct Authority's Disclosure Guidance and Transparency Rules.
For further information from Avacta Group plc, please
contact:
Avacta Group plc Tel: +44 (0) 844
Alastair Smith, Chief Executive 414 0452
Officer www.avacta.com
Tony Gardiner, Chief Financial
Officer
finnCap Ltd Tel: +44 (0) 207
Geoff Nash / Giles Rolls - Nominated 220 0500
Adviser www.finncap.com
Tim Redfern / Alice Lane / Nikita
Jain - Corporate Broking
Tel: +44 (0) 203
WG Partners 705 9318
Nigel Birks / Nigel Barnes Tel: +44 (0) 203
David Wilson / Claes Spang 705 9217
www.wgpartners.co.uk
Zyme Communications (Trade and Tel: +44 (0)7787
Regional Media) 502 947
Katie Odgaard katie.odgaard@zymecommunications.com
Yellow Jersey PR (Financial Tel: +44 (0)7764
Media and IR) 947137
Sarah Hollins avacta@yellowjerseypr.com
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R)
technology which is a novel engineered alternative to antibodies
that has wide application in Life Sciences for diagnostics,
therapeutics and general research and development.
Antibodies dominate markets worth in excess of $100bn despite
their shortcomings. Affimer technology has been designed to address
many of these negative performance issues, principally; the time
taken to generate new antibodies, the reliance on an animal's
immune response, poor specificity in many cases, and batch to batch
variability. Affimer technology is based on a small protein that
can be quickly generated to bind with high specificity and affinity
to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an
in-house focus on immuno-oncology and bleeding disorders as well as
partnered development programmes. Avacta is commercialising
non-therapeutic Affimer reagents through licensing to developers of
life sciences research tools and diagnostics.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1. Details of the person discharging managerial
responsibilities / person closely associated
--- ---------------------------------------------------------------------------------------------------------------------
a) Name Michael Albin
--- ------------------------ -------------------------------------------------------------------------------------------
2. Reason for the Notification
--- ---------------------------------------------------------------------------------------------------------------------
a) Position/status Non - Executive Director
--- ------------------------ -------------------------------------------------------------------------------------------
b) Initial Initial notification
notification/Amendment
--- ------------------------ -------------------------------------------------------------------------------------------
3. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- ---------------------------------------------------------------------------------------------------------------------
a) Name Avacta Group Plc
--- ------------------------ -------------------------------------------------------------------------------------------
b) LEI 2138009U3EG31OPMGH36
--- ------------------------ -------------------------------------------------------------------------------------------
4. Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- ---------------------------------------------------------------------------------------------------------------------
a) Description of Ordinary shares
the Financial of 10p
instrument, type
of instrument
---
Identification GB00BYYW9G87
code
--- ------------------------ -------------------------------------------------------------------------------------------
b) Nature of the As set out in the Company's announcement of 23 February 2016, on 22 February 2016 Mr
transaction Albin
entered into a binding commitment to purchase new Avacta shares amounting to 50% of his
contractual
non-executive director fee per quarter and the New Ordinary Shares represent his
investment
for the period of 1 January 2018 to 31 March 2018.
--- ------------------------ -------------------------------------------------------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) ------------- ----------
36.25 pence 10,345
------------- ----------
--- ------------------------ -------------------------------------------------------------------------------------------
d) Aggregated information:
* Aggregated volume See above
* Price
--- ------------------------ -------------------------------------------------------------------------------------------
e) Date of the transaction 9 April 2018
--- ------------------------ -------------------------------------------------------------------------------------------
f) Place of the London Stock Exchange, AIM
transaction Market (XLON)
--- ------------------------ -------------------------------------------------------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEUKVORWNASRAR
(END) Dow Jones Newswires
April 09, 2018 09:58 ET (13:58 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2024 to May 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From May 2023 to May 2024